ADMA Biologics, Inc.
- ADMA
- NASDAQ
- Biotechnology
- Plasma-Derived Biologics
- Immune Disorder Therapies
$11.07
Today +3.65%Quote Oct 19, 2026, 08:00 PM UTC
+21.51%over the last month
Max drawdown −4.4%From 1-month high 0.0%3 months +28.9%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About ADMA Biologics
ADMA Biologics, Inc. functions as a biopharmaceutical company specializing in the development, manufacturing, and commercialization of advanced biologic therapies derived from blood plasma. These specialized products are engineered to address immune system disorders and infectious diseases, catering to markets across the United States and internationally.
Where the money comes from
Q4 2024 revenue $117.2M
- ADMA BioManufacturing Segment$116.4M99.3%
- Plasma Collection Centers Segment$804,0000.7%
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
644
Founded
2004
Market value
$2.48B
Quote Oct 19
Floor
$11.05
0.2% below price
Resistance
$11.42
3.2% above price
Price vs analyst targets
10 analysts
Lowest target
$17.00Highest target
$21.00
$17.00Highest target
$21.00
- Price $11.07
- Average target $18.67
- Analysts' target range
The price is below even the lowest analyst target. Analysts' average target sits about 69% higher.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about ADMAPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free